2nd Quarter - Report

EMPIRE CONSULTING GROUP for GILEAD SCIENCES INC.

Period 2nd Quarter 2023 Filed Jul 19, 2023 Signed by Mike McKay, Principal

Official filing
Firm
EMPIRE CONSULTING GROUP
Client
GILEAD SCIENCES INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. WH Cancer Moonshot program. HIV/AIDS funding. HR 235 Triple Negative Breast Cancer Research & Education

LobbyistCovered position, as disclosed
E. BRANDON GARRETT New Chief of Staff-Rep. Robin Kelly; Policy Dir.-Political Advisor to VP Joseph Biden for 2012 Obama/Biden Campaign; Policy Dir.-Cong. Black Caucus/Rep. Emanuel Cleaver II; Leg. Dir.-Rep. Marcia Fudge; and Leg. Asst.-Rep. Wm. Jefferson
BRIAN GREER New Prof. Staff-House Armed Services Comm.; Military Leg Asst.- Sen. Charles Schumer; Spec Asst.-Off. of Sec. of Defense; Military Leg Asst.- Rep. John Boccieri; Military Leg Asst.-Rep. Parker Griffith; Leg Asst., Staff Asst. & Leg Corr.-Rep. David Scott
MIKE MCKAY —

Contacted: SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 235 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.